title: Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
abstract: The 11th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology that were identified through the continuous systematic search of MEDLINE. For this electronic search, a broad search filter covering all topics in hemato-oncology was combined with a highly sensitive search filter for randomized studies. This report covers publications from February 1, 2009, through August 31, 2009 (including electronic publications). For this 7-month period, 6344 potentially interesting articles were screened to identify 121 controlled clinical trials (randomized controlled trials or quasi-randomized clinical trials) of therapeutic interventions in hematologic malignancies.
authors.affiliation: Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, D-50924 Cologne, Germany. kathrin.bauer@uk-koeln.de
authors.forename: Kathrin
authors.initials: K
authors.lastname: Bauer
authors.forename: Christine
authors.initials: C
authors.lastname: Herbst
authors.forename: Corinne
authors.initials: C
authors.lastname: Brillant
authors.forename: Ina
authors.initials: I
authors.lastname: Monsef
authors.forename: Sabine
authors.initials: S
authors.lastname: Kluge
authors.forename: Nicole
authors.initials: N
authors.lastname: Skoetz
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage; D000069461:Bendamustine Hydrochloride; D001761:Bleomycin / Q000008:administration & dosage; D002699:Chlorambucil / Q000008:administration & dosage; D018849:Controlled Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D015444:Exercise; D006397:Hematinics / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D006397:Hematinics; D009588:Nitrogen Mustard Compounds; D001761:Bleomycin; D002699:Chlorambucil; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D001374:Azacitidine; D011241:Prednisone